GH Research Plc (GHRS)
27.69
+0.33
(+1.21%)
USD |
NASDAQ |
Sep 02, 14:24
GH Research Free Cash Flow : -52.46M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.46M |
| March 31, 2026 | -47.20M |
| December 31, 2025 | -45.04M |
| September 30, 2025 | -42.31M |
| June 30, 2025 | -40.53M |
| March 31, 2025 | -40.70M |
| December 31, 2024 | -41.74M |
| September 30, 2024 | -39.96M |
| June 30, 2024 | -37.65M |
| March 31, 2024 | -35.96M |
| Date | Value |
|---|---|
| December 31, 2023 | -33.26M |
| September 30, 2023 | -32.73M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | -19.78M |
| December 31, 2021 | -14.88M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Atai Beckley, Inc. | -134.54M |
| Avadel Pharmaceuticals Plc | -- |
| Jazz Pharmaceuticals Plc | 1.508B |
| Eli Lilly & Co. | 13.56B |
| Perrigo Co. Plc | 119.30M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -14.94M |
| Cash from Investing (Quarterly) | 6.295M |
| Cash from Financing (Quarterly) | 111.51M |
| Free Cash Flow Per Share (Quarterly) | -0.2248 |
| Free Cash Flow to Equity (Quarterly) | -14.88M |
| Free Cash Flow to Firm (Quarterly) | -14.87M |
| Free Cash Flow Yield | -3.00% |